RxDoctor Payments Data

Frank Bonura, MD

Gynecology · Smithtown, NYNPI 1881784817

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,150 of the $6,207 with a category attached, or 83.0%. Astellas Pharma US Inc accounts for 88.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $5,590 and has fallen 99.3% since, to $41 in 2024. Among gynecology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,207in general payments, 2019–2025

Across 23 payments — averaging $269.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$6K
  • Radius Health, Inc.$273
  • Amgen$193
  • Lupin Inc.$123
  • AMAG Pharmaceuticals, Inc.$69
  • Therapeuticsmd, Inc.$20
  • plus $18 from 1 others

What the payments were for

  • Speaking & faculty fees$5,15083%
  • Travel & lodging$3606%
  • Food & beverage$60510%
  • Education$921%

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,207 in reported general payments places this provider in the 90th percentile of 240 gynecology providers in New York.

See all gynecology providers in New York

Medicare billing

Part B allowed, 2024
$156,273
Medicare patients
177
Services billed
1,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab90$154,013
Estradiol49$8,148
YuvafemEstradiol24$5,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$193$154,01390 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 240 gynecology providers in New York.

Other gynecology in Smithtown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →